01—Abstract
Summary
Summary of the 8-K filed October 24, 2024. Cited figures are marked; the original filing is the authoritative source.
Guardant Health (Nasdaq: GH) filed an 8-K on October 24, 2024 to report a board change rather than a financial or operational event.
Effective October 21, 2024, the Board increased its size to ten directors and appointed Roberto A. Mignone as a Class I director, with a term expiring at the 2025 Annual Meeting. He was also placed on the Audit Committee.
Mignone is the Founder and Managing Partner of Bridger Management LLC, a long-term equity investment firm with a healthcare focus, and he previously co-founded Blue Ridge Capital LLC. The filing contains no financial results, guidance, or disclosed transaction amounts beyond standard director compensation. Mignone receives the Company's standard non-employee director package under its Amended Non-Employee Director Compensation Program: a stock option award and an RSU award, each valued at $362,500a.
Both vest over roughly three years, with 25%b vesting on the first anniversary of his appointment and the remainder vesting monthly thereafter. He is also entering the Company's standard indemnification agreement. The filing states there are no arrangements under which he was selected and no related-party transactions reportable under Item 404(a).
For investors, the main significance is governance. Adding a healthcare-focused investor with long-term equity experience to the Audit Committee may signal shareholder engagement and oversight, and the press release links the appointment to strengthening product offerings across the care continuum following the FDA approval of Shield for early-stage colorectal cancer screening. The filing itself does not link the appointment to any specific strategic or financial outcome.
02—Key points
Key Highlights
- Roberto A. Mignone was appointed to Guardant Health's Board of Directors effective October 21, 2024, and the Board expanded from nine to ten seats to accommodate him.
- Mignone joins the Audit Committee, a notable governance role for a director with an investment management background.
- He is the Founder and Managing Partner of Bridger Management LLC, a firm founded in 2000 that focuses on long-term equity strategies with substantial healthcare research depth.
- His director compensation totals $362,500 in stock options and $362,500 in RSUs, vesting over about three years on a standard schedule.
- The filing discloses no related-party transactions, no selection arrangements, and no financial results or guidance changes.
- The press release ties the appointment to Guardant's expanding product portfolio following the FDA approval of Shield for early-stage colorectal cancer screening.
03—Questions
Frequently Asked Questions
Does this 8-K include any financial results or guidance changes?
No. The filing reports only a board appointment, the related compensation terms, and an indemnification agreement. It contains no revenue, earnings, or guidance information.
Why did the Board increase its size to ten directors?
The filing does not state a reason for the expansion. It says only that the Board increased its size to ten and then appointed Mignone to fill one of the new seats.
What is Mr. Mignone's background, and could it create conflicts of interest?
He founded Bridger Management LLC, an investment firm with a healthcare focus, and previously co-founded Blue Ridge Capital LLC. The filing reports no transactions in which he has a reportable interest under Item 404(a), so no related-party conflict is disclosed. Investors may still want to monitor any investment-related interests given his role on the Audit Committee.
What compensation does Mr. Mignone receive?
He receives the standard non-employee director package: a stock option award and an RSU award, each valued at $362,500. Each vests 25% after one year and the remainder monthly over the following three years, subject to continued service.
When does Mr. Mignone's board term end?
His term expires at the 2025 Annual Meeting of Stockholders, or when a successor is duly elected and qualified, or upon his earlier death, resignation, or removal.
04—Continue